ArticleBMC gastroenterology2025
Relationship between serum total bilirubin levels and primary loss of response to Infliximab therapy in Crohn's disease patients.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
aimsCrohn’s disease (CD) is a chronic inflammatory bowel disease whose global prevalence continues to rise. Infliximab (IFX) is the first-line biologic for moderate-to-severe CD, yet a high rate of loss of response (LOR) limits its long-term efficacy. Existing predictive tools are either costly or insufficient. This study aimed to evaluate the predictive value of serum total bilirubin (sTB) in combination with routine clinical and hematological parameters for IFX treatment outcomes in CD patients.
methodsWe retrospectively enrolled 85 CD patients who were treated with IFX (July 2019-December 2021) and stratified them into training (n = 59) and validation (n = 26) sets. LOR was defined as failure to achieve biochemical remission (fecal calprotectin < 250 µg/g or ≥ 50% reduction from baseline) at 26 weeks post-IFX. Baseline data (demographics, laboratory values, imaging, and clinical features) were analyzed via univariate and multivariate logistic regression. A nomogram integrating significant predictors was developed and validated.
resultsAmong the 85 patients, 48 (56.5%) developed LOR. Patients with LOR had significantly lower baseline sTB levels (5.86 vs. 7.88 µmol/L, P = 0.001). Multivariate analysis revealed sTB (odds ratio (OR) = 0.83, 95% confidence interval (CI): 0.64–0.99), L1 Montreal phenotype (OR = 0.23, 95% CI: 0.10–0.85), perianal lesions (OR = 3.84, 95% CI: 1.27–11.57), and elevated monocyte percentage (OR = 1.20, 95% CI: 1.00-1.49) as independent predictors of LOR. The combined model in overall patients achieved an area under the curve (AUC) of 0.80 for LOR prediction, outperforming sTB alone (AUC = 0.715). Internal validation confirmed robust performance (training AUC = 0.82; validation AUC = 0.78).
conclusionLower baseline sTB levels were associated with LOR to IFX. A simple nomograms based on sTB, L1 phenotypes, perianal lesions, and elevated monocyte percentages provide a simple tool for the identification of CD patients at high risk of LOR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.